V

Vectus Biosystems Ltd
ASX:VBS

Watchlist Manager
Vectus Biosystems Ltd
ASX:VBS
Watchlist
Price: 0.13 AUD Market Closed
Market Cap: 6.9m AUD

Operating Margin

-11 494.1%
Current
Improving
by 6 121.4%
vs 3-y average of -17 615.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-11 494.1%
=
Operating Income
AU$-2.2m
/
Revenue
AU$18.8k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-11 494.1%
=
Operating Income
AU$-2.2m
/
Revenue
AU$18.8k

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Vectus Biosystems Ltd
ASX:VBS
6.9m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
382B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
160.4B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.6B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.2B USD
Loading...
No Stocks Found

Market Distribution

Lower than 91% of companies in Australia
Percentile
9th
Based on 3 951 companies
9th percentile
-11 494.1%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Vectus Biosystems Ltd
Glance View

Market Cap
6.9m AUD
Industry
Biotechnology

Vectus Biosystems Ltd. operates as a drug discovery and development company. The company is headquartered in Rosebery, New South Wales. The company went IPO on 2016-02-23. The firm has developed treatments for fibrosis and high blood pressure, which include treatment for four of the diseases in the fibrotic franchise, namely heart, kidney, liver and lung disease. Its lead compound VB0004, which is aimed at treating the loss of functional tissue to fibrosis or scarring and high blood pressure. The firm has also developed a technology, Accugen for measuring the amount of Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Using its platform technology, the Company has constructed a library of approximately 200 small molecules with varying degrees of anti-hypertensive and anti-fibrotic properties. Accugen is developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions.

VBS Intrinsic Value
0.004 AUD
Overvaluation 97%
Intrinsic Value
Price
V
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-11 494.1%
=
Operating Income
AU$-2.2m
/
Revenue
AU$18.8k
What is Vectus Biosystems Ltd's current Operating Margin?

The current Operating Margin for Vectus Biosystems Ltd is -11 494.1%, which is above its 3-year median of -17 615.6%.

How has Operating Margin changed over time?

Over the last 3 years, Vectus Biosystems Ltd’s Operating Margin has increased from -4 600 300% to -11 494.1%. During this period, it reached a low of -4 600 300% on May 30, 2022 and a high of -4 409.7% on Dec 31, 2023.

Back to Top